Journal
HUMAN MUTATION
Volume 41, Issue 6, Pages 1171-1182Publisher
WILEY
DOI: 10.1002/humu.24007
Keywords
ERK phosphorylation studies; in vitro phosphatase assay; molecular dynamics simulations; Noonan syndrome; PTPN11; SHP2
Categories
Funding
- Medical Research Council [MR/N008324/1] Funding Source: Medline
- MRC [MR/N008324/1] Funding Source: UKRI
Ask authors/readers for more resources
Germline PTPN11 mutations cause Noonan syndrome (NS), the most common disorder among RASopathies. PTPN11 encodes SHP2, a protein tyrosine-phosphatase controlling signaling through the RAS-MAPK and PI3K-AKT pathways. Generally, NS-causing PTPN11 mutations are missense changes destabilizing the inactive conformation of the protein or enhancing its binding to signaling partners. Here, we report on two PTPN11 variants resulting in the deletion or duplication of one of three adjacent glutamine residues (Gln(255)-to-Gln(257)). While p.(Gln257dup) caused a typical NS phenotype in carriers of a first family, p.(Gln257del) had incomplete penetrance in a second family. Missense mutations involving Gln(256) had previously been reported in NS. This poly-glutamine stretch is located on helix B of the PTP domain, a region involved in stabilizing SHP2 in its autoinhibited state. Molecular dynamics simulations predicted that changes affecting this motif perturb the SHP2's catalytically inactive conformation and/or substrate recognition. Biochemical data showed that duplication and deletion of Gln(257) variably enhance SHP2's catalytic activity, while missense changes involving Gln(256) affect substrate specificity. Expression of mutants in HEK293T cells documented their activating role on MAPK signaling, uncoupling catalytic activity and modulation of intracellular signaling. These findings further document the relevance of helix B in the regulation of SHP2's function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available